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Abstract 
Capsules coated with polyelectrolytes and co-encapsulating adipose stem (ASCs) and endothelial 
(ECs) cells with surface modified microparticles are developed. Microparticles and cells are freely 
dispersed in a liquified core, responsible to maximize the diffusion of essential molecules and 
allowing the geometrical freedom for the autonomous three-dimensional (3D) organization of cells. 
While the membrane wraps all the instructive cargo elements within a single structure, the 
microparticles provide a solid 3D substrate for the encapsulated cells. Our hypothesis is that inside 
this isolated biomimetic 3D environment, ECs would lead ASCs to differentiate into the osteogenic 
lineage to ultimately generate a mineralized tissue in vivo. For that, capsules encapsulating only 
ASCs (MONO capsules) or co-cultured with ECs (CO capsules) are subcutaneously implanted in 
nude mice up to 6 weeks. Capsules implanted immediately after production or after 21 days of in 
vitro osteogenic stimulation are tested. The most valuable outcome of the present study is the 
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mineralized tissue in CO capsules without in vitro pre-differentiation, with similar levels compared to 
the pre-stimulated capsules in vitro. We believe that the proposed bioencapsulation strategy is a 
potent self-regulated system, which might find great applicability in bone tissue engineering. 
 
1. Introduction 
The regeneration of large bone defects remains a major concern in the orthopaedic field. To avoid 
the potential disadvantages of autografts and allografts, namely their limited supply and disease 
transmission potential [1], engineered bone constructs have been proposed as promising 
alternatives in clinical applications. Donor-site morbidity associated to cell isolation (both 
osteoblasts or bone marrow-derived mesenchymal stem cells) and limited proliferative capacity of 
primary osteoblasts are major challenges in providing adequate numbers for transplantation [2,3]. In 
addition to bone marrow, adipose tissue has been identified as a source of multipotent cells that due 
to the capacity to differentiate into adipogenic, chondrogenic, myogenic, and osteogenic lineages 
are seen as promising for tissue regeneration [4,5]. Moreover, adipose tissue is often available in an 
abundant quantity after a relatively easy harvesting. However, controlling mesenchymal 
differentiation and engineering bone in vivo are challenging accomplishments, as it often leads to 
heterotypic and inferior osseous tissues. Additionally, when osteogenesis is aimed at, angiogenesis 
must be considered since it plays an important role during the development and maturation of bone 
[6,7]. The induction of orchestrated osteo- and angiogenesis by biochemical stimulation [8,9] or by 
co-culturing osteoprogenitor and endothelial cells [10-13] has been shown to better induce bone 
tissue formation, as well as to improve survival of the engineered tissues. Particularly, considering 
native bone vascular network, osteoprogenitor cells inevitably interact with endothelial cells (ECs) in 
a synergetic fashion [14,15]. While endothelial cells secrete numerous regulatory molecules that 
influence the differentiation and activity of bone forming cells [16-19], osteoprogenitor cells release 
diverse pro-angiogenic growth factors [11,13,20,21]. To mimic such concept, one could envisage 
the in vitro development of a single reservoir that contain instructive signals to, upon implantation, 
generate bone-like tissues. In this context, we propose a novel bioencapsulation strategy whose in 
vivo performance is assessed for the first time. With this work we expect to highlight the potential of 
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liquified and multilayered capsules as an alternative methodology to the commonly used 3D porous 
structures/hydrogels for TE. For that, mesenchymal stem and endothelial cells were both isolated 
from the adipose tissue and co-cultured within liquified and multilayered capsules. Following multi-
scale assembling strategies [22], the capsules are composed by three essential components: (i) a 
permselective nanostructured membrane that wraps the liquefied core of the capsule ensuring 
permeability to essential molecules for cell survival, and the creation of a single reservoir to facilitate 
the implantation procedure of multiple components; (ii) poly(L-lactic acid) (PLLA) microparticles 
surface functionalized with plasma treatment and collagen I that create a 3D microenvironment for 
the encapsulated cell and act as cell adhesion sites; and (iii) adipose stem (ASCs) and endothelial 
(ECs) cells. The membrane was produced by layer-by-layer (LbL) technique, which is a versatile, 
low-cost technique, and more importantly for bioencapsulation systems, can be performed under 
mild conditions [23,24]. We hypothesized that within the controlled environment of capsules, 
endothelial cells would promote the osteogenic differentiation of ASCs due to their specific crosstalk, 
leading to the formation of a mineralized tissue in vivo. The design of the experiment is represented 
in Scheme 1. Capsules containing only ASCs (MONO capsules) or ASCs and ECs (CO capsules) 
were produced 21 days before the implantation (day -21), and subsequently cultured in osteogenic 
differentiation medium to stimulate in vitro the differentiation of the ASCs. At the day of implantation 
(day 0), the production of MONO and CO capsules was repeated. Additionally, capsules without 
encapsulated cells (MATERIAL) were also produced. All the produced capsules, i.e. after 21 days of 
in vitro osteogenic stimulation or freshly prepared, were implanted up to 6 weeks in nude mice, each 
one with two craniolateral-oriented pockets subcutaneously created by blunt dissection. Three 
capsules of the same formulation were implanted at each pocket (Scheme 1A). At predetermined 








2. Materials and methods 
2.1 Cells isolation and characterization 
Subcutaneous adipose tissue from liposuction procedures was used to isolate both human ASCs 
[25] and human ECs [26]. The collected tissues were obtained under a cooperation agreement 
between the 3B’s Research Group and Hospital da Prelada (Porto, Portugal), after approval of the 
respective ethical committees. Patient's informed consent and anonymity were assured. Samples 
were transported in phosphate-buffered saline (PBS, Sigma-Aldrich) supplemented with penicillin-
streptomycin (10%, pen-strep, Gibco) and kept at 4ºC for a maximum of 24 h. Lipoaspirates were 
washed with PBS and incubated with collagenase type II A (0.05% w/v, Sigma-Aldrich) for 45 
minutes at 37ºC in a shaking water bath. The digested samples were filtered (200 µm) and 
centrifuged (800 g, 10 min, 4ºC). The obtained stromal vascular fraction (SVF) was resuspended in 
erythrocyte lysis buffer (pH 7.4) containing ammonium chloride (155 mM, Merk), potassium 
bicarbonate (5.7 mM, Riedel-de-Häen), and ethylenediaminetetraacetic acid (0.1 M, EDTA, Sigma-
Aldrich) in distilled water. After 10 min of incubation at room temperature (RT), the mixture was 
centrifuged (300 g, 5 min). To obtain the ASCs cultures, the red blood cell-free SVF was 
resuspended in α-MEM medium (Invitrogen) supplemented with fetal bovine serum (10%, FBS, 
Invitrogen) and pen-strep (1% v/v). The ECs cultures were obtained from the red blood cell-free 
SVF that was resuspended in EndoGroTM-MV-VEGF complete media kit (Millipore Iberica). ECs 
were plated in cell culture flasks, previously coated with gelatin (0.7% w/v, porcine skin type A, 
Sigma-Aldrich) for 30 min at 37ºC. Culture medium was changed 48 h after initial plating and then 
every 3-4 days for both cell phenotypes. 
The phenotypic profile of the isolated ASCs and ECs was assessed by a flow cytometer (BD 
FACSCalibur, CellQuest v3.3 software, BD Biosciences). Mesenchymal (CD105-FITC, Arium; 
CD90-APC, and CD73-PE, BD Biosciences), endothelial (CD31-APC, Citomed) and hematopoietic 
(CD34-PE, BD Biosciences) markers were quantified. Briefly, the isolated cells were harvested by 
TrypLETM Express solution (Life Technologies) at 37ºC for 5 min, and centrifuged. Samples were 
resuspended in PBS solution containing bovine serum albumin (3% w/v, BSA, Sigma-Aldrich) and 
the specified antibodies at the dilutions defined by the manufacture’s specifications. After 20 min at 
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RT, samples were subsequently washed with PBS, centrifuged, fixed in formaldehyde (1% v/v, 
Sigma-Aldrich) for analysis. More than 90% of the isolated ASCs were positive for all the 
mesenchymal stem cells markers tested, whilst lacking the endothelial marker CD31. Additionally, 
ASCs expression for CD34 was bellow 2%. On the other hand, for ECs the expression of the 
endothelial marker CD31 was 98% and for CD34 around 2%. 
 
2.2 Microparticles production and surface functionalization 
Poly(L-lactic acid) microparticles (µPLLAs) were produced by an oil/water (o/w) emulsion technique 
and surface modified with collagen I after plasma treatment as similarly described in our previous 
reports [27-30]. Briefly, PLLA (5% w/v, Mw~1,600-2,400, 70% crystallinity, Polysciences) was 
dissolved in methylene chloride (CH2Cl2, Fisher Chemical). Under agitation, this solution was added 
to polyvinyl alcohol (0.5%, PVA, Sigma-Aldrich). After 2 days at RT, the produced µPLLAs were 
subsequently collected, washed with distilled water, and lyophilized (Cryodos, Telstar) for 3 days. 
Microparticles were then placed in a plasma reactor chamber (PlasmaPrep5, Gala Instrumente) 
fitted with a radio frequency generator. Air was used as the working atmosphere. A glow discharge 
plasma (0.2 mbar, 30V, 15 min) was created. Subsequently, microparticles (500 mg) were 
immersed for 4 h at RT in collagen I solution (1200 µg, rat protein tail, Gibco). 
 
2.3 Mono- and co-cultures set up 
Sodium alginate (1.5% w/v, ALG, ~250 cP, low viscosity from brown algae, Sigma-Aldrich) was 
dissolved in sodium chloride (0.15 M, NaCl, Enzymatic) buffered at pH 7 with MES hydrate (25 mM, 
Sigma-Aldrich). The solution was sterilized by 0.22 µm filtration prior mixing with the cells. At 90% 
confluence, ASCs (passage 2) and ECs (passage 4-6) were detached using TrypLETM Express 
solution (Life Technologies) at 37ºC for 5 min. PBS was added and the cell suspensions were 
centrifuged for 5 min at 300 g.  Cells (ASCs alone or mixed with ECs, 1:1 ratio) resuspended in the 
alginate solution (5x106 cells per mL of alginate) were added to the microparticles (50 mg.mL-1 of 
alginate) and then used to produce liquified capsules containing ASCs alone (MONO capsules) or in 
co-culture with ECs (CO capsules). 
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2.4 Liquified multilayered capsules production 
All the conditions used to produce liquified capsules (the combination of the polyelectrolytes, 
concentration, pH, number of layers, and time of adsorption and liquefaction) were optimized in our 
previous studies [27-30]. Briefly, alginate solutions containing cells were added drop wise using a 
21 G needle to a calcium chloride solution (0.1 M, CaCl2, VWR) buffered at pH 7 with MES hydrate 
(25 mM, Sigma-Aldrich). After 20 min at RT, alginate hydrogel particles were collected and rinsed in 
a washing solution of NaCl (0.15 M). The external membrane was processed by layer-by-layer 
adsorption. Hydrogel particles were subsequently immersed in poly-L-lysine (PLL, Mw ~ 30,000-
70,000, pH 7, Sigma-Aldrich), ALG solution (pH 7), chitosan (CHT, pH 6, water-soluble highly 
purified, viscosity 107 mPa.s, Mw = 2.7x105 g.mol-1, 83% degree of deacetylation, Protasan UP CL 
213, NovaMatrix), and, ultimately, in ALG solution again. All the polyelectrolyte solutions (0.5 
mg.mL-1) were prepared in NaCl (0.15 M) containing MES hydrate (25 mM). Following a 10 min 
adsorption period for each polymer, the excess of macromolecules was removed by immersion in 
NaCl (0.15 M) for 5 min. This process was repeated three times in order to obtain a 12-layered 
membrane. Coated hydrogel particles were immersed in EDTA (20 mM) at pH 7 for 5 min to liquefy 
the alginate core. To induce osteogenic differentiation in vitro, MONO and CO capsules were 
cultured for 21 days in supplemented medium composed by complete EndoGroTM-MV-VEGF 
medium supplemented with β-glycerophosphate (10 mM, Sigma-Aldrich), ascorbic acid (50 µg.mL-1), 
and dexamethasone (10 nM, Sigma-Aldrich). 
 
2.5 Lipophilic fluorescent labelling 
Prior encapsulation, ASCs and ECs were incubated with lipophilic dyes, namely 3,3′ -
dioctadecyloxacarbocyanine perchlorate (DIO, green) and 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DIL, red), respectively. Cells were incubated with each 
dye (1 mL, 2 µM per 1x106 cells) at 37 °C for 10 min. Then, MONO and CO capsules were 
produced as previously described encapsulating fluorescently labelled cells. Capsules were 




2.6 DNA and alkaline phosphatase activity quantification 
MONO and CO capsules cultured in osteogenic differentiation medium for 21 days were analysed 
after cell lysis for DNA amount and alkaline phosphatase activity (ALP). Four capsules per well were 
suspended in 1 mL of ultra-pure water. After 1 h in a 37ºC shaking water bath, the solutions were 
frozen at -80ºC overnight. Samples were defrosted and used according to the specifications of the 
kit (Quant-iTTM PicoGreen® dsDNA assay kit, Life Technologies). A standard curve was generated 
with the provided dsDNA solution. After 10 min of incubation at RT, fluorescence was read at an 
excitation wavelength of 485/20 nm and 528/20 nm of emission using a microplate reader (Gen 5 
2.01, Synergy HT, Biotek). Then, the activity of ALP in the remaining solutions was quantified. 
Briefly, a substrate solution (pH 9.8) was prepared by dissolving 4-nitrophenylphosphate disodium 
salt hexahydrate (0.2% w/v, Sigma-Aldrich) in diethanolamine (1 M, Sigma-Aldrich). Each sample 
(20 µL) was mixed with the prepared substrate solution (60 µL). After 45 min at 37ºC protected from 
light, the reaction was stopped with 80 µL of a NaOH (2 M) and EDTA (0.2 mM) solution. A standard 
curve was prepared with diluted series of 4-nitrophenol solution (10 mM, Sigma-Aldrich). 
Absorbance was read at 405 nm in a microplate reader (Gen 5 2.01, Synergy HT, Biotek). ALP 
activity results were normalized with dsDNA quantification data of MONO capsules. 
 
2.7 Mineralization analysis 
MONO and CO capsules cultured in osteogenic differentiation medium for 21 days were washed in 
PBS, and processed in an automatic spin tissue processor (STP120-2, Microm) for histological 
analysis. Samples were embedded in paraffin and cut into sections of 5 µm thickness using a 
microtome (HM355S, Microm). To visualize calcium-rich deposits, sections were deparaffinized and 
subsequently immersed in alizarin red staining solution for 5 min at RT. Samples were then 
mounted and analysed by microscopy (Axio Imager Z1m, Zeiss).  
 
2.8 Animals surgery, euthanasia, and implants retrieval 
The animal experimentation project was approved by the institutional Animal Welfare Body (SECVS 
032/2015) and the National Authority Direção Geral de Alimentação e Veterinária. Five week-old 
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male nude mice (average weight of 25 g) were used to subcutaneously implant MONO and CO 
capsules, either freshly prepared or after 21 days in vitro in osteogenic differentiation medium, and 
capsules without encapsulated cells (MATERIAL). Four mice were used for each formulation and at 
each timepoint (1, 3, and 6 weeks). Under surgical sterile conditions, animals were anaesthetized 
with an intraperitoneal injection of a mixture of ketamine (75 mg.kg-1, Imalgene®, Merial) and 
metedomidine (1 mg.kg-1, Domitor®, Orion). One medial incision of approximately 0.7 cm was 
performed in the dorsum of the mice and two craniolateral-oriented pockets were subcutaneously 
created by blunt dissection. Three capsules were inserted into each pocket. Pockets without 
capsules were also used as control (EMPTY). Subsequently, the panniculus carnosus and the skin 
were carefully sutured with non-resorbable 4/0 sutures. After the surgical procedure, the animals 
were induced to recover from anaesthesia with an intraperitoneal injection of Atipazemol (1 mg.kg-1, 
Antisedan, Orion). The animals were kept housed together (different conditions in each cage) with 
standard diet and water ad libitum during all the time of the experiment. After 1, 3, and 6 weeks of 
implantation, the animals were euthanized by carbon dioxide inhalation. The implanted capsules 
and the respective surrounding tissue were explanted from each animal. The collected explants 
were subjected to macroscopic observation and fixed in 10% formalin for 24 h at RT. Samples were 
then processed for standard histological evaluation. 
 
2.9 In vivo histological analysis 
The explants were processed in an automatic ethanol-xylene spin tissue processor (STP120-2, 
Microm) and then embedded in paraffin. Histological sections (5 µm) were obtained using a 
microtome (HM355S, Microm, ThermoFisher Scientific). Before each histological staining, the 
sections were automatically deparaffinized and rehydrated (HMS740, Microm, ThermoFisher 
Scientific). After each staining protocol, unless otherwise specified, the sections were immediately 
dehydrated and immersed in xylene, before being mounted (Entellan, Millipore). Ultimately, the 





2.9.1 Hematoxylin and eosin (H&E) staining 
The samples for H&E staining protocol were automatically processed (HMS740, Microm, 
ThermoFisher Scientific). Briefly, histological sections were subsequently immersed in hematoxylin 
(BioOptica) and after bluing in an ammonia solution (1% v/v), in eosin y (BioOptica).  
 
2.9.2 CD31 immunohistochemistry 
Antigen retrieval was performed in heat-mediated (95-100ºC) sodium citrate buffer (10 mM, Sigma-
Aldrich) for 20 min. After cool down for 20 min, endogenous peroxidases were inactivated with 
hydrogen peroxide (3% v/v, AnalaR Normapur) and non-specific binding blocked with horse serum 
incubation (2.5% NHS, Vectastain Universal Quick Kit, Vector Laboratories) for 30 min at RT. The 
sections were incubated with the primary antibody rabbit polyclonal anti-human to CD31 (1:50 
diluted in PBS with NHS, Abcam) in a humidified chamber at 4ºC overnight. The second antibody 
(Vectastain Universal Quick Kit, Vector Laboratories) was added for 1 h at RT, and the stained 
revealed with a DAB solution prepared according to manufacturer’s specifications (Vectastain 
Universal Quick Kit, Vector Laboratories). Sections were counterstained with hematoxylin 
(BioOptica) before microscopic analysis. 
 
2.9.3 Masson’s trichrome staining 
Sections were stained for 5 min in a solution containing azure B (0.5 g, Sigma-Aldrich), ammonium 
iron (5 g, ammonium iron sulfate (III) dodecahydrate, Millipore) and distilled water (100 mL). 
Sections were then subsequently stained with hematoxylin (BioOptica) and picric ethanol (1% w/v, 
Sigma-Aldrich) for 5 min each. After 10 min washing in running tap water, sections were stained 
with the solutions from the Trichrome Stain Masson kit (Sigma-Aldrich) according to the 
manufacturer’s specifications. 
 
2.9.4 Osteopontin immunofluorescence 
The antigen retrieval was performed in a heat-mediated sodium citrate buffer (10 mM, Sigma-
Aldrich). Non-specific binding was blocked by immersion in BSA (3% w/v) for 30 min at RT. 
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Samples were then incubated overnight at 4ºC with the primary antibody rabbit anti-human 
osteopontin (1:100 in 1% BSA, Abcam). After a PBS washing, samples were incubated for 1 h at RT 
with the secondary antibody anti-rabbit AlexaFluor 488 (1:500 in 1% BSA, Molecular Probes). 
Samples incubated only with the secondary antibody were used as controls. Ultimately, samples 
were subsequently counterstained with DAPI (1 mg.mL-1 diluted 1:1000 in PBS, Sigma-Aldrich) for 5 
min at RT, immediately mounted (Permafluor, ThermoFisher Scientific), and analysed by 
fluorescence microscopy (Axio Imager Z1m, Zeiss). The percentage of green intensity was 
measured by Image J software (version 1.44o). Each image (n=4) was split in the three RGB 
channels. In the green channel (G) the intensity of fluorescence was quantified with a threshold of 
45-255. 
Alizarin Red Staining: To assess the presence of calcium-rich deposits (red), the sections were 
immersed in alizarin red solution (2% w/v, Sigma-Aldrich) for 5 min at RT. The percentage of red 
intensity was measured by Image J software (version 1.44o). Each image  (n=4) was split in the 
three RGB channels. In the red channel (R) the intensity of colour was quantified with a threshold of 
0-206. 
 
2.10 Statistical analysis 
All the results were expressed as mean ± standard deviation. Significant differences between the 





3.1 In vitro evaluation of the capsules 
Prior implantation, ASCs and ECs grown in 2D cell culture flasks were fluorescently marked with 
lipophilic dyes. The fluorescently marked cells were then encapsulated in MONO (Figure 1A) and 
CO (Figure 1B) capsules. Samples were immediately visualized by confocal microscopy. In MONO 
capsules, only green fluorescence corresponding to ASCs presence could be detected, while in CO 
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capsules both green and red fluorescence were detected, identifying respectively ASCs and ECs. 
The dyes assay allowed to visualize the random distribution of ASCs and ECs encapsulated within 
the capsules liquified environment. Cells were only labelled prior to encapsulation for the lipophilic 
fluorescence assay. 
After 21 days of culture in osteogenic differentiation medium, the secretion of the late osteogenic 
marker osteopontin (OP) was confirmed in MONO (Figure 1C) and CO capsules  (Figure 1D). OP 
is a biomarker of mature osteoblast phenotypical behaviour, being widely used in osteogenic 
differentiation strategies [31,32]. It is a multifunctional extracellular glycoprotein primarily involved in 
the regulation of mineral deposition [33]. Among the non-collagenous matrix proteins present in 
bone, OP acts as a unique interfacial adhesion molecule, thus being responsible to maintaining the 
structural integrity of bone and bone/implant systems [34,35]. 
Additionally, mineralization was qualitatively assessed by alizarin red staining (Figure 1E and F), 
confirming the deposition of calcium. Ultimately, capsules were tested for DNA quantification 
(Figure 1G) and ALP activity (Figure 1H). As expected, day 0 capsules have the lowest DNA 
amount compared to day 21 capsules. This indicates that the encapsulated cells in day 21 capsules 
have proliferated during the in vitro culture. Moreover, the efficient encapsulation of the cells was 
proven by the double amount of DNA detected in the CO capsules that corresponds to the 
additional and equal amount of endothelial cells used. CO capsules after 21 days of culture 
continued to present the highest DNA amount, which seems to indicate the absence of deleterious 
effects of the system. Figure 1H illustrates the ALP activity normalized per µg DNA of the MONO 
capsules at day 0 and after 21 days of in vitro culture. Again, day 0 capsules have a significant 
lower ALP activity compared to day 21 capsules since the latter were cultured in vitro in 
supplemented medium to stimulate the osteogenic differentiation of the ASCs. Importantly, CO 







3.2 In vivo histological assessment 
 
3.2.1 Morphological analysis 
Histological analysis of explanted samples stained with H&E (Figure 2) showed good integration of 
all types of capsules within the surrounding host tissue. At the first week of implantation, the 
fragmentation of the layer-by-layer membrane of the capsules was visible. It seems that the 
disruption of the membrane occurred gradually since the encapsulation contents, composed by cells 
and microparticles, remained grouped at the site of the implantation. In addition, the histological 
evaluation with H&E staining also revealed the presence of various blood vessels in MONO and CO 
capsules, while in MATERIAL capsules only few vessels could be observed. In the empty control, 
the presence of blood vessels could not be detected. 
After 6 weeks of implantation, immunostaining of CD31 (Figure 3) was performed in MONO and CO 
capsule. As evidenced, the capsules were permeated to blood vessels. However, the CD31 was not 
specific for the endothelium. Particularly in the CO capsules, more areas with non-specific 
endothelium staining could be detected along the sections, which jeopardizes the visualization of 
the permeable blood vessels expressing CD31. This could be attributed to the fact that the co-
encapsulated endothelial cells are also expressing CD31. The presence of collagen was then 
assessed by Masson’s Trichrome staining. As evidenced in Figure 4, the presence of collagen 
(blue staining) could be visualized mostly in MONO and CO capsules with 21 days of previous in 
vitro culture. Notably, although in less quantify, the presence of collagen in the newly deposited 
ECM could also be detected in CO capsules without in vitro stimulation. Additionally, the staining 
also allowed visualizing the presence of blood vessels with intraluminal red blood cells inside the 
capsules environment. Importantly, the presence of a dense layer of fibrotic connective tissue 
surrounding the capsules could not be visualized, which highlights the biotolerability of the capsules. 
 
3.2.2 Osteogenesis evaluation 
The osteogenic marker OP was qualitatively detected by fluorescence microscopy (Figure 5). As 
expected, OP was expressed within in vitro pre-differentiated MONO and CO capsules (day 21 
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capsules). At the first week of implantation, OP could be earlier detected in pre-differentiated CO 
capsules. Latter, with increasing implantation time, the expression of OP could also be detectable in 
CO capsules without in vitro osteogenesis stimulation (day 0 capsules). The detection of OP with 
increased implantation time indicates the commitment of the encapsulated stem cells towards the 
osteogenic lineage. Only scarce fluorescence could be found in the material capsules as well as in 
day 0 MONO capsules formulations, indicating that osteogenic differentiation did not occur. 
Corroborating the OP results, mineralization (Figure 6) occurred in the pre-differentiated MONO 
and CO capsules, as well as in CO capsules without in vitro osteogenesis (day 0 capsules). 
Mineralization increased with the implantation time, and after 6 weeks of implantation calcium-rich 
deposits (stained in red) covered the entire region of the capsules. In the MONO capsules without 




In the current study, we demonstrate for the first time the in vivo osteogenic differentiation of stem 
cells driven by co-culture with endothelial cells within liquified and multilayered capsules containing 
solid microparticles. 
Among the different bioencapsulation systems proposed [36-40], the central issue is related with the 
diffusion of nutrients to prevent necrosis at the bulk of implanted materials. In fact, the consensus in 
all tissue engineering fields is that improved vascularization is the crux of all future scaffold designs 
[6,7,41]. Particularly in bone tissue engineering, engineered scaffolds transplanted to patients to 
restore or improve the functions of damaged tissue have often failed to produce the desired results 
due to a deficient oxygen and nutrient diffusion. In order to address this issue, we developed a 
bioencapsulation system, in which the core is in a liquid state, hence maximizing mass 
transportation within all the regions of the construct. However, the majority of cells used in tissue 
engineering are anchorage dependent, and consequently a physical support to process different 
cellular metabolisms is required. Therefore, along with the encapsulated cells, solid microparticles 
were incorporated inside the liquified environment of the capsules, which act as cell adhesion sites. 
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Additionally, microparticles also allowed creating a biomimetic 3D environment inside the capsules. 
Surrounding the liquified core loaded with the encapsulated cells and microparticles is the layer-by-
layer membrane. As shown, the thin multilayer remained stable during 21 days of in vitro culture, 
and allowed the required diffusion of essential molecules for cell survival. The membrane also 
allowed the diffusion of osteogenic differentiation factors added to the culture medium that led to in 
vitro pre-osteogenic stimulation of MONO and CO capsules. The presence of the membrane was 
also essential to assemble all the encapsulated components into a single reservoir. Having a single 
structure encapsulating all the different components facilitated the implantation process, while 
avoiding their dispersion to other regions of the body. However, notwithstanding the stability shown 
in vitro, after the first week of implantation the histological analysis of the capsules revealed that the 
membrane was disrupted. Nevertheless, since the disruption of the membrane occurred only at 
some areas, the core contents of the capsules remained mobilized and aggregated at the site of 
implantation. The partial disruption could be explained by the fact that the capsules were implanted 
subcutaneously into created pockets, so they were under a squeeze effect between the host tissues. 
Additionally, as time increases, the presence of blood vessels could have also contributed to the 
disruption of the flexible membrane that together with the liquified core of capsules could not offer a 
rigid surface. However, the disruption of the membrane proved to be a great outcome since the 
blood vessels transport oxygen and nutrients necessary to the transplanted cells and to the tissue 
surrounding the implanted capsules. Our main hypothesis was that the co-encapsulation of 
endothelial cells with stem cells within the capsules environment would lead stem cells to 
differentiate into the osteogenic lineage and, ultimately, led to the formation of a mineralized tissue. 
Different fundamental studies [42-44] have been show that ASCs stimulate blood vessel growth due 
to the secretion of many pro-angiogenic factors, such as VEGF [11,13,21]. This explains the 
abundant presence of blood vessels in all capsules. Furthermore, endothelial cells also secrete 
numerous regulatory molecules for the differentiation and activity of bone forming cells [16-19]. 
However, in vivo this interaction is poorly characterized mainly because to the absence of 
appropriate engineered systems. Facca et al. [45] reported that although in vitro no substrate was 
required, the osteogenic differentiation of embryonic stem cells after in vivo implantation with 
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microparticles incorporating BMP-2 and VEGF only occurred after incorporation of the contents in 
an alginate gel as a substrate. This was mainly attributed to the fact that the alginate matrix 
improved contact between the cells and the microparticles releasing system. In our strategy, the 
encapsulated stem and endothelial cells remained grouped due to the capsules structure. We 
believe that this has directly influenced the reported in vivo outcome by promoting a higher 
exposure to pro-angiogenic and osteogenic factors released by stem and endothelial cells, 
respectively. This interaction explains the significant advance of this work, namely the in vivo 
osteogenesis with a mineralized and vascularized matrix observed in the CO capsules implanted 
immediately after production. This is an interesting outcome, indicating that CO capsules might be 
readily implanted after production into a bone defect since osteogenesis occurred in vivo without 
requiring the standard in vitro stimulation of 21 days in differentiation medium. The co-culture 
contribution is supported by the absence of mineralized tissue in the MONO capsules also 
implanted immediately after production. The pre-differentiation strategy of MONO and CO capsules 
during 21 days in vitro in culture medium containing osteogenic differentiation factors also 
demonstrated that the osteogenic differentiation pattern was maintained in vivo. However, the pre-
differentiation of CO capsules, since endothelial cells are co-encapsulated, might result in a 
prevascularization in vitro. In bone TE, however, the in vivo success of in vitro prevascularization 
has so far been limited. Rouwkema et al. [46] have shown that vascular structures obtained from 
co-cultures of human umbilical vein endothelial cells (HUVECs) and human mesenchymal stem 
cells (hMSCs) were stable and organized into a more mature vascularization network after 
implantation. However, anastomosis of the invading vessels to the in vitro created vasculature was 
limited. Therefore, a vascularized osteogenic system that does not require in vitro culture before 
implantation is of great importance in TE strategies. 
The present study also allowed reinforcing the potential of the proposed capsules for bone 
regeneration, as proposed in our previous in vitro study [29]. In the referred in vitro study, it was 
demonstrated that the co-encapsulation of ECs lead ASCs to differentiate into the osteogenic 
lineage inside the liquified and multilayered capsules with microparticles, even in the absence of two 
major osteogenic differentiation factors, namely dexamethasone and ascorbic acid. Additionally, it 
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was demonstrated that CO capsules released BMP-2 and VEGF, which evidences the potential of 
the capsules as a cytokine delivery system. In the present study, we could confirm the potential of 
capsules for the first time in vivo without any in vitro stimulation. 
In future work, it is our intention to fully validate their potential in a bone defect using 
immunocompetent models such as humanized models, and thus to study in more detail the 
relevance of the system in a clinical approach. 
 
5. Conclusion 
In this study, MONO and CO capsules with or without in vitro osteogenic pre-differentiation were 
subcutaneously implanted in nude mice up to 6 weeks. The in vivo implantation of capsules did not 
elicit a severe infiltration of inflammatory cells, demonstrating the biotolerability of the liquified 
capsules. Sign of necrosis, either in the host tissue surrounding the implanted capsules or in the 
newly formed tissue inside the capsules, could not be detected, which is a major concern when 
implanting 3D systems. The significant advance of this work is that the co-encapsulation of 
endothelial cells with stem cells led to the formation of a mineralized tissue in vivo. This work is also 
a unique demonstration of the in vivo performance of a liquified and multilayered capsule containing 
microparticles and a co-culture of endothelial and stem cells. Considering the reported findings, we 
suggest the use of CO capsules as self-regulated reservoirs that after production can be readily 
implanted. By using this formulation we can incorporate different kinds of active molecules aimed at 
different applications, such as gene therapy, drug delivery, or tissue engineering. We believe that 
the developed capsules will find great applicability in bone regeneration, but also in other tissue 
engineering domains of complex tissue restoration. 
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Scheme 1 – Schematic representation of the experimental design. Capsules encapsulating only 
adipose stem cells (MONO capsules) or adipose stem cells and endothelial cells (CO capsules) 
were produced (day -21) and cultured in vitro in osteogenic differentiation medium for 21 days. At 
the day of implantation (day 0), MONO, CO and capsules without cells (MATERIAL) were freshly 
prepared. Capsules were implanted in nude mice up to 6 weeks. (A) Three capsules of the same 
formulation were implanted at each pocket.  Scale bar is 1 cm. (B) After 1, 3, and 6 weeks, implants 
were retrieved. The localization of the implanted capsules could be macroscopically visualized. 
Scale bar is 1 cm. 
 
Figure 1 – Confocal images of (A) MONO and (B) CO capsules encapsulating cells at day 0 
previously labelled with DIO (green, ASCs) and DIL (red, ECs) lipophilic dyes. Scale bar is 200 µm. 
(C) Osteopontin immunofluorescence (green) in MONO and (D) CO capsules cultured in osteogenic 
medium for 21 days. Cells nuclei were counterstained with DAPI (blue). Scale bar is 200 µm. (E) 
Alizarin red staining on histological sections of MONO and (F) CO capsules cultured in osteogenic 
differentiation medium for 21 days. Calcium deposits were stained in red. Scale bar is 40 µm. (G) 
DNA quantification and (H) ALP activity of MONO and CO capsules freshly prepared at the day of 
implantation (0 days of in vitro culture) or after 21 days in osteogenic differentiation medium (21 
days of in vitro culture). Four capsules per well were tested (n=5). Boxplots are presented in Spear 
style. 
 
Figure 2 – H&E staining of representative sections from MONO and CO capsules (implantation at 
day 0 and day 21) and from controls, namely capsules without cells (Material) and pockets without 
capsules (Empty). Explants were retrieved after 1, 3, and 6 weeks of implantation (scale bar: 50µm). 
Abbreviations and signs used: microparticles (>), residual material of the liquified environment of 




Figure 3 – CD31 immunohistochemistry of representative sections from MONO and CO capsules 
(implantation at day 0 and after 21 days of in vitro culture). The presence of blood vessels is 
evidenced with squares. Explants were analysed after 6 weeks of implantation. Scale bar is 40 µm. 
 
Figure 4 – Masson’s trichrome staining of representative sections from MONO and CO capsules 
(implantation at day 0 and after 21 days of in vitro culture). Explants were analysed after 6 weeks of 
implantation. Collagen is stained in blue. Scale bar is 40 µm. 
 
Figure 5 – Osteopontin (green) immunohistochemistry counterstained with DAPI (blue) of 
representative sections from MONO can CO capsules (implantation at day 0 and day 21) and, as 
control, from capsules without encapsulated cells (Material). Explants were analysed after 1, 3, and 
6 weeks of implantation. The insets represent the percentage and the respective standard deviation 
(n=4) of green fluorescence quantified by Image J. Scale bar is 50 µm. 
 
Figure 6 – Alizarin red staining of representative sections from MONO and CO capsules of 
representative sections from MONO and CO capsules (implantation at day 0 and day 21) and, as 
control, from capsules without encapsulated cells (Material). Explants were analysed after 1, 3, and 
6 weeks of implantation. Mineralization spots are stained in red. Insets represent the percentage 















































































Statement of Significance 
 
 
The diffusion efficiency of essential molecules for cell survival is a main issue in cell encapsulation. 
Former studies reported the superior biological outcome of encapsulated cells within liquified 
systems. However, most cells used in TE are anchorage-dependent, requiring a solid substrate to 
perform main cellular processes. We hypothesized that liquified capsules encapsulating 
microparticles are a promising attempt. Inspired by the multiphenotypic cellular environment of bone, 
we combine the concept of liquified capsules with co-cultures of stem and endothelial cells. After 
implantation, results show that co-cultured capsules without in vitro stimulation were able to form a 
mineralized tissue in vivo. We believe that the present ready-to-use TE strategy requiring minimum 
in vitro manipulation will find great applicability in bone tissue engineering. 
 
